Sai Life Sciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹659 Cr +22.7% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
SL

Sai Life Sciences Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Sai Life Sciences Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹556Cr
+26.4% YoY
+3.5% QoQ
Net profit
₹100Cr
+85.2% YoY
+19% QoQ
Margin
34%
+7 pp YoY
+7 pp QoQ
Price₹1,457
Market cap₹29.6K Cr
P/E83.4

The short version

Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%.

From Sai Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand.
  • The company foresees 15% to 20% revenue CAGR over a three-year period, with some years possibly outperforming this range.
  • New capacity expansions, including a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity), are planned to support growth.
  • Current capacity utilization is around 60%, leaving headroom for near-term growth without immediate incremental capacity.
  • Growth will be bolstered by both development and commercial contracts, with diversification across multiple molecules and modalities.
  • Visibility from customer discussions indicates ongoing active engagements and pipeline progress feeding future capacity requirements.

2 more points from Sai Life Sciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sai Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%.
  • Starting expansion of a new mixed-use site in Hyderabad, expected to be operational within 18-24 months; will include non-GMP, peptide, and GMP capacities.
  • Animal health Phase I expansion targeted for completion by March ’27, enabling validation and commercialization of veterinary API products; current investment less than INR 50 crores with an additional INR 70-75 crores planned for next phase.
  • Ongoing R&D expansions:
  • First phase at Hyderabad Unit 8 commissioning in Q4 FY’26 with ~200 fume hoods.
  • New process facility R&D building commissioning by Sept ’26, doubling process R&D capacity.
  • Peptide process development and pilot facility targeted for Sept ’26.
  • OEB laboratories for ADC capabilities completion by Oct ’26.

2 more points from Sai Life Sciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sai Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - Capacity expansions are in progress based on "relative visibility" from ongoing customer conversations, indicating a healthy pipeline and expected demand. - The company is adding 450 KL capacity in FY’27 and is starting a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity) with a 18-24 month timeline. - Expansion decisions are balanced against customer visibility, with cautious but forward-looking capex aligned with active pipeline products, mostly in Phase 2 moving to Phase 3.

2 more points from Sai Life Sciences Ltd's call on order book

Create a free account to keep reading this call

Sai Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sai Life Sciences Ltd Q3 FY26 results — key figures

Sai Life Sciences Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue556440+26.4%537+3.5%
Operating profit (EBITDA)188120+56.7%146+28.8%
Operating margin34%27%+7 pp27%+7 pp
Profit before tax13472+86.1%112+19.6%
Net profit (PAT)10054+85.2%84+19%
EPS (₹)4.752.59+83.4%4.00+18.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹659 Cr, net profit ₹98 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sai Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sai Life Sciences Ltd Q3 FY26 results?

Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%.

What is Sai Life Sciences Ltd share price analysis?

Sai Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 83.4 with a market cap of ₹29,600 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sai Life Sciences Ltd planning capital expenditure?

Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%.

Keep Sai Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.